节点文献
新型凝血酶抑制剂阿加曲班
Argatroban,a new direct thrombin inhibitor
【摘要】 阿加曲班(argatrOban)是一种凝血酶抑制剂,可直接与凝血酶的催化位点结合,迅速可逆的与凝血块结合并溶解凝血酶,其半衰期为39~51min,停止治疗后迅速恢复凝血功能,通过监测抗凝血参数调整其使用剂量。现介绍阿加曲班的药理学、药效学、药动学及不良反应、相互作用等方面的研究进展。
【Abstract】 Argatroban is the only direct thrombin inhibitor, binding to the catalytic site of the thrombin molecule. It is able to rapidly and reversibly bind to both clot-bound and soluble thrombin, reducing extension of existing thromboses. Its short half-life (39 to 51 minutes) and binding reversibility allow rapid onset of action and rapid restoration of normal haemostasis upon cessation of therapy. As an ideal anticoagulant for both the prophylaxis and treatment of heparin-induced thrombocytopenia (HIT) and associated thrombotic complications, argatroban offers a predictable dose response that is well correlated with changes in anticoagulant parameters and is minimally monitored. This paper reviews pharmacology, pharmacodynamics, pharmacokinetics, safety and drug interactions of argatroban.
【Key words】 argatroban; thrombin inhibitor; pharmacodynamics, pharmacokinetics, clinical evaluation;
- 【文献出处】 中国新药杂志 ,Chinese New Drugs Journal , 编辑部邮箱 ,2005年02期
- 【分类号】R973
- 【被引频次】46
- 【下载频次】1209